Document Detail


Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
MedLine Citation:
PMID:  11935217     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We sought to determine whether the de novo resistance of M5076 ovarian sarcoma cells, which show sensitivity to pirarubicin (THP), to doxorubicin (DOX) is due to differences in the transport characteristics between THP and DOX, and the results were compared with those for drug-sensitive Ehrlich ascites carcinoma cells. METHODS: The in vitro cytotoxicity of the drugs was assessed by means of the tetrazolium dye assay. Transport experiments were performed by the rapid centrifugation method. RESULTS: In an in vitro cytotoxicity experiment, M5076 cells showed lower sensitivity to DOX than to THP, and the cytotoxicity of THP and DOX toward M5076 cells was lower than toward Ehrlich cells, and these results were similar to those of an in vivo experiment. This was due to the much lower expression of topoisomerase II in M5076 cells than in Ehrlich cells. The amount of intracellular DOX was found to be significantly lower than that of THP in both cell types, and furthermore, little free intracellular DOX was observed in M5076 cells, indicating that the low sensitivity of M5076 cells to DOX was partially a result of the low amount of intracellular DOX. There was no difference in the efflux rate, but there was an apparent difference in the uptake efficiency of the carrier between THP and DOX. CONCLUSIONS: These findings suggest that the cytotoxicities of THP and DOX toward M5076 and Ehrlich cells depend, at least in part, on the uptake efficiency of the carrier.
Authors:
Katsuhito Nagai; Kazuki Nagasawa; Yasuyuki Sadzuka; Masayuki Tsujimoto; Kohji Takara; Noriaki Ohnishi; Teruyoshi Yokoyama; Sadaki Fujimoto
Related Documents :
7136187 - Growth characteristics of anaerobically treated ehrlich ascites tumor cells after reaer...
6223337 - Aspects of chalone action.
740057 - Cytotoxic and cancerostatic effect of 1,4-dithiaanthraquinone-2,3-dicarbonitrile.
15943987 - Ovarian carcinoma cells and il-1beta-activated human peritoneal mesothelial cells are p...
10634517 - Acquired antiestrogen resistance in mcf-7 human breast cancer sublines is not accomplis...
17059357 - Why does pancreatic overstimulation cause pancreatitis?
Publication Detail:
Type:  Journal Article     Date:  2002-01-08
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  49     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-04-05     Completed Date:  2002-05-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  244-50     Citation Subset:  IM    
Affiliation:
Department of Environmental Biochemistry, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibiotics, Antineoplastic / pharmacokinetics,  toxicity*
Biological Transport / drug effects
Carcinoma, Ehrlich Tumor / metabolism,  pathology*
Cell Survival / drug effects*
Dinitrophenols / pharmacology
Doxorubicin / analogs & derivatives,  pharmacokinetics,  toxicity*
Female
Humans
Kinetics
Mice
Ovarian Neoplasms / metabolism,  pathology*
Sarcoma / metabolism,  pathology
Temperature
Time Factors
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Dinitrophenols; 23214-92-8/Doxorubicin; 72496-41-4/pirarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Next Document:  Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.